Blood Clot in right lung; This spontaneous case was reported by a patient and describes the occurrence of PULMONARY THROMBOSIS (Blood Clot in right lung) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOFACITINIB CITRATE (XELJANZ XR) for an unknown indication.    No Medical History information was reported.   In April 2017, the patient started TOFACITINIB CITRATE (XELJANZ XR) (Oral) 11 milligram once a day. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Nov-2021, the patient experienced PULMONARY THROMBOSIS (Blood Clot in right lung) (seriousness criteria hospitalization and medically significant). The patient was hospitalized from 24-Nov-2021 to 25-Nov-2021 due to PULMONARY THROMBOSIS. The patient was treated with APIXABAN (ELIQUIS) at a dose of 5 milligram twice a day. At the time of the report, PULMONARY THROMBOSIS (Blood Clot in right lung) was resolving. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered PULMONARY THROMBOSIS (Blood Clot in right lung) to be not related.    Patient stated that his doctors think the clot might have been related to receiving the Moderna COVID vaccine but. He stated the clot was very painful. He stated he was discharged home on 25-Nov-2021 on treatment with Eliquis (5 mg twice daily). He stated he was feeling much better now, but he gets tired easily.  His Xeljanz refill was scheduled for delivery on 28-Dec-21. Patient stated he thought his rheumatologist was aware of his blood clot, but he was not sure.  Patient reported that he was scheduled to see a lung specialist on 29-Dec-2021, but the office had to reschedule his appointment.  Patient reported he was wearing compression stockings.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in  Company comment: This spontaneous case concerns a 60-year-old male patient with no medical history reported, who experienced the unexpected, serious (hospitalization and medically significant) event of pulmonary thrombosis (AESI) an unknown time after a dose of mRNA-1273. The patient was hospitalized for 24 hours for pulmonary thrombosis in the right lung. Treatment included apixaban twice daily and compression socks. Concomitant medication of tofacitinib (prescribed for an unknown rheumatological condition) is a risk factor for the event. Outcome was reported as recovering. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 60-year-old male patient with no medical history reported, who experienced the unexpected, serious (hospitalization and medically significant) event of pulmonary thrombosis (AESI) an unknown time after a dose of mRNA-1273. The patient was hospitalized for 24 hours for pulmonary thrombosis in the right lung. Treatment included apixaban twice daily and compression socks. Concomitant medication of tofacitinib (prescribed for an unknown rheumatological condition) is a risk factor for the event. Outcome was reported as recovering. The benefit-risk relationship of mRNA-1273 is not affected by this report.